Updated
The most significant concentration Evolent Health discloses is Molina Healthcare at 25.7%, classified MEDIUM by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Evolent Health’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
“10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'”
“10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'”
“10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'”
“10-K Item 1A: 'Our four largest partners in terms of revenue, Molina Healthcare, Inc. ("Molina"), Cook County Health and Hospitals System, Florida Blue and Centene Corporation comprised 25.7%, 16.4%, 14.2% and 12.2%, respectively, of our revenue'”
Evolent Health's revenue is spread across four large health-plan partners rather than concentrated in one. Molina Healthcare represents 25.7% of revenue, a medium-share dependency, while Cook County Health and Hospitals System at 16.4%, Florida Blue at 14.2%, and Centene Corporation at 12.2% are each low-share dependencies individually. All four are counterparty-specific relationships rather than structural features of the business — each is a distinct payer partner whose contract renewal, renegotiation, or termination could affect revenue. Taken together, though, the fact that the largest single partner is only medium-share, and the next three are each low-share, suggests a more diversified partner base than a single dominant-customer profile would imply: no one relationship on its own looks likely to move the overall verdict, but a simultaneous disruption across two or more of the top four could compound quickly given how close their individual shares are to one another. This reads as a portfolio of meaningful counterparty dependencies rather than a single acute customer risk.
For the engine’s reasoning on EVH’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| GDRX | GoodRx Holdings, Inc. | 1 | 0 | 0 | 1 |
| BTSG | BrightSpring Health Services, I | 0 | 2 | 0 | 2 |
| EVH● | Evolent Health, Inc | 0 | 1 | 3 | 4 |
| CTEV | Claritev Corporation | 0 | 1 | 1 | 2 |
| DOCS | Doximity, Inc. | 0 | 1 | 1 | 2 |
| CERT | Certara, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.